<i>Lacticaseibacillus rhamnosus</i> LRa05 in the treatment of acute diarrhea in children: a randomized controlled trial.
Chen. Ke K; Zeng. Kaihong K; Jin. Shanshan S; Ma. Yu Y; Cai. Limei L; Xu. Ping P; Nie. Yang Y; Luo. Li L; Yu. Qinghua Q; Liu. Changqi C
Key Findings
- Diarrhea lasted about 22 hours less in the probiotic group (121 h vs 144 h).
- LL‑37 levels in stool were significantly higher after probiotic treatment.
- The probiotic increased beneficial Bifidobacterium longum and reduced potentially harmful bacteria like Enterococcus faecium and Bacteroides fragilis.
Practical Outcomes
- For anyone looking to support gut health or immune function, a short course of LRa05 at 5 × 10⁹ CFU/day may speed recovery from acute diarrhea and boost the body’s own antimicrobial peptide LL‑37. This protocol could be adapted for adult gut‑support regimens, though dosing would need adjustment.
Summary
Giving kids aged 0‑3 a daily probiotic called LRa05 (5 billion CFU) cut the length of watery diarrhea and helped their gut bacteria become healthier, while also raising levels of the natural antimicrobial peptide LL‑37.
Abstract
The goal of this study is to assess the efficacy and safety of <i>Lacticaseibacillus rhamnosus</i> LRa05, as an adjunct to the treatment of acute watery diarrhea in children. Eligible diarrheal children were randomized into intervention group (IG, <i>n</i> = 57) and control group (CG, <i>n</i> = 54), and given probiotics or placebo, respectively. The total duration of diarrhea in the IG (121.4 ± 13.7 h) was significantly shorter than that in the CG (143.9 ± 19.8 h, <i>p</i> < 0.001). More children in the IG showed improvements in diarrhea than those in the CG for both per protocol analysis (70.2 vs. 46.3%, <i>p</i> = 0.01) and intention-to-treat analysis (66.7 vs. 41.7%, <i>p</i> = 0.003). The LL-37 levels in the IG was markedly higher than that in the CG after the intervention (4349.35 ± 1143.86 pg./g vs. 3682.49 ± 869.21 pg./g, <i>p</i> = 0.039). The intervention led to higher abundance of <i>Bifidobacterium longum</i> and lower abundance of <i>Enterococcus faecium</i>, <i>Lactobacillus rhamnosus</i>, and <i>Bacteroides fragilis</i> (<i>p</i> < 0.05). LRa05 treatment upregulated the functional genes of gut microbiota involving immunity regulation. Administration of the <i>Lacticaseibacillus rhamnosus</i> LRa05 at a dose of 5 × 10<sup>9</sup> CFU/day to children aged 0-3 years resulted in shorter duration of diarrhea, faster improvement in fecal consistency, and beneficial changes in gut microbiome composition and gene functions. The present study has been approved and registered in the Chinese Clinical Trial Registration Center with the registration number of ChiCTR2100053700 (https://www.chictr.org.cn/showproj.html?proj=141082).
Study Information
pubmed
2024
2024-11-15T00:00:00.000Z
10.3389/fnut.2024.1479186
1
40